307 results
8-K
EX-99.1
SEEL
Seelos Therapeutics Inc
19 Mar 24
Other Events
4:05pm
. The disease is progressive, meaning the symptoms get worse over time. The majority of ALS cases (90 percent or more) are considered sporadic. This means
424B3
SEEL
Seelos Therapeutics Inc
15 Mar 24
Prospectus supplement
4:15pm
participant in the registrational Phase II/III study for the treatment of SCA. In March 2023, we announced that in order to focus the majority of our … data based on the guidance from regulatory agencies.
In March 2023, we announced that in order to focus the majority of our resources on the ongoing
8-K
EX-10.1
egf7xoyjq7p6moyi4w9
30 Jan 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-4.1
g3n95q4hvn1ucguhvime
30 Jan 24
Entry into a Material Definitive Agreement
4:01pm
424B5
86vitjg
30 Jan 24
Prospectus supplement for primary offering
6:05am
8-K
EX-4.1
yo8f we4ax
30 Nov 23
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
4:59pm
8-K
EX-1.1
5kgs1ia
30 Nov 23
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
4:59pm
8-K
EX-4.2
4ey 99qr6
30 Nov 23
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
4:59pm
424B5
55www ghmuzt2cnkt
30 Nov 23
Prospectus supplement for primary offering
4:58pm
424B5
82dbmj8 eeon0e8
28 Nov 23
Prospectus supplement for primary offering
4:06pm